330350 — Withus Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Annual income statement for Withus Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 June 30th	2020 June 30th	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	51,732	52,393	57,419	64,680	80,119
Cost of Revenue
Gross Profit	31,989	32,967	33,525	38,335	48,638
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	40,797	42,658	52,533	59,803	72,210
Operating Profit	10,935	9,735	4,886	4,878	7,909
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11,023	10,036	5,240	4,158	9,141
Provision for Income Taxes
Net Income After Taxes	8,661	8,039	4,264	2,479	7,959
Net Income Before Extraordinary Items
Net Income	8,661	8,039	4,264	2,479	7,959
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,661	8,039	4,264	2,479	7,959
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	745	691	347	187	603
Dividends per Share